JP2023510958A - 操作された免疫細胞 - Google Patents

操作された免疫細胞 Download PDF

Info

Publication number
JP2023510958A
JP2023510958A JP2022544061A JP2022544061A JP2023510958A JP 2023510958 A JP2023510958 A JP 2023510958A JP 2022544061 A JP2022544061 A JP 2022544061A JP 2022544061 A JP2022544061 A JP 2022544061A JP 2023510958 A JP2023510958 A JP 2023510958A
Authority
JP
Japan
Prior art keywords
cells
antigen
immune cell
seq
immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022544061A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510958A5 (enExample
Inventor
フィッシャー，ジョナサン
チェスター，ケリー
アンダーソン，ジョン
ミランダ ロタ，エンリケ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Biomedica PLC
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Biomedica PLC, UCL Business Ltd filed Critical UCL Biomedica PLC
Publication of JP2023510958A publication Critical patent/JP2023510958A/ja
Publication of JP2023510958A5 publication Critical patent/JP2023510958A5/ja
Priority to JP2025154666A priority Critical patent/JP2026001027A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
JP2022544061A 2020-01-22 2021-01-21 操作された免疫細胞 Pending JP2023510958A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025154666A JP2026001027A (ja) 2020-01-22 2025-09-18 操作された免疫細胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2000934.6A GB202000934D0 (en) 2020-01-22 2020-01-22 Engineered immune cells
GB2000934.6 2020-01-22
PCT/GB2021/050128 WO2021148788A1 (en) 2020-01-22 2021-01-21 Engineered immune cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025154666A Division JP2026001027A (ja) 2020-01-22 2025-09-18 操作された免疫細胞

Publications (2)

Publication Number Publication Date
JP2023510958A true JP2023510958A (ja) 2023-03-15
JP2023510958A5 JP2023510958A5 (enExample) 2024-01-24

Family

ID=69636913

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022544061A Pending JP2023510958A (ja) 2020-01-22 2021-01-21 操作された免疫細胞
JP2025154666A Pending JP2026001027A (ja) 2020-01-22 2025-09-18 操作された免疫細胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025154666A Pending JP2026001027A (ja) 2020-01-22 2025-09-18 操作された免疫細胞

Country Status (8)

Country Link
US (1) US20230049025A1 (enExample)
EP (1) EP4093431A1 (enExample)
JP (2) JP2023510958A (enExample)
CN (1) CN115315270A (enExample)
AU (1) AU2021211185A1 (enExample)
CA (1) CA3165473A1 (enExample)
GB (1) GB202000934D0 (enExample)
WO (1) WO2021148788A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230227575A1 (en) * 2022-01-10 2023-07-20 Expression Therapeutics, Llc Engineered T Cells
GB202204272D0 (en) * 2022-03-25 2022-05-11 Ucl Business Ltd Method for engineering innate-like lymphocytes
EP4622715A1 (en) * 2022-11-22 2025-10-01 Expression Therapeutics, LLC Engineered t cells
EP4648854A1 (en) * 2023-01-10 2025-11-19 Expression Therapeutics, LLC Engineered t cells
GB202416012D0 (en) * 2024-10-30 2024-12-11 Ucl Business Ltd Engineered immune cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170166657A1 (en) * 2015-08-13 2017-06-15 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) In Immunotherapy
WO2019134991A1 (en) * 2018-01-08 2019-07-11 Iomx Therapeutics Ag Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
EP1916257A1 (en) * 2006-10-27 2008-04-30 Charite-Universitätsmedizin Berlin GD2 peptide mimotopes for anticancer vaccination
CN107523545A (zh) * 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的杀伤性细胞及其用途
US20190307799A1 (en) * 2016-09-23 2019-10-10 The Regents Of The University Of Michigan Engineered lymphocytes
WO2018118494A2 (en) * 2016-12-22 2018-06-28 Xiaotong Song Use of car-modified human natural killer cells to treat cancer
EP3600357A4 (en) * 2017-03-31 2021-01-06 The Board of Trustees of the Leland Stanford Junior University METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING
EP3621988A1 (en) * 2017-05-09 2020-03-18 Bellicum Pharmaceuticals, Inc. Methods to augment or alter signal transduction
WO2020021045A2 (en) * 2018-07-26 2020-01-30 Ospedale Pediatrico Bambino Gesù (Opbg) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170166657A1 (en) * 2015-08-13 2017-06-15 Kim Leslie O'Neill Macrophage CAR (MOTO-CAR) In Immunotherapy
WO2019134991A1 (en) * 2018-01-08 2019-07-11 Iomx Therapeutics Ag Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A.CAPSOMIDIS, ET AL., MOLECULAR THERAPY, vol. 26, no. 2, JPN6025002634, 2018, pages 354 - 365, ISSN: 0005512634 *
J.FISHER, ET AL., SCI. SIGNAL., vol. Vol.12(598): eaax1872, JPN6025002633, pages 1 - 34, ISSN: 0005512635 *
J.ZENG, ET AL., PLOS ONE, vol. Vol.14(5): e0216815, JPN6025002632, 2019, pages 1 - 20, ISSN: 0005512636 *
R.ESSER, ET AL., J.CELL.MOL.MED, vol. 16, no. 3, JPN6025002635, 2012, pages 569 - 581, ISSN: 0005512633 *

Also Published As

Publication number Publication date
JP2026001027A (ja) 2026-01-06
EP4093431A1 (en) 2022-11-30
AU2021211185A1 (en) 2022-08-04
CA3165473A1 (en) 2021-07-29
CN115315270A (zh) 2022-11-08
US20230049025A1 (en) 2023-02-16
GB202000934D0 (en) 2020-03-04
WO2021148788A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
JP7462777B2 (ja) 新規キメラ抗原受容体とその使用
JP6867347B2 (ja) 免疫療法のためのエンゲージャー細胞
US20230242877A1 (en) Immune cell comprising chimeric antigen receptor and use thereof
US20210145880A1 (en) Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
AU2026202375A1 (en) Chimeric antigen receptors targeting cancer
JP2026001027A (ja) 操作された免疫細胞
CN109575143B (zh) 双特异性cd20-cd19-car及其应用
US20220202864A1 (en) Bcma-targeting engineered immune cell and use thereof
WO2021129559A1 (zh) T细胞受体融合蛋白及其用途
EP3967329A1 (en) Engineered immune cell targeting bcma and use thereof
US11332513B2 (en) Chimeric antigen receptors having GITR intracellular domain as co-stimulatory domain
CN111733186A (zh) 靶向cd19的人源化嵌合抗原受体制备及其应用
CN112638428A (zh) 嵌合抗原受体肿瘤浸润淋巴细胞
KR102842684B1 (ko) 향상된 t-세포 수용체 star 및 이의 적용
CN114057890A (zh) 新型共刺激结构域及其用途
US20230321242A1 (en) Chimeric antigen receptor (car)-expressing cells recognizing cea
WO2025102013A1 (en) Rhabdovirus g proteins having one or more cysteine-rich regions and uses thereof
KR20220167330A (ko) Cd22-표적화된 키메라 항원 수용체, 그의 제조 방법 및 그의 적용
US20190345257A1 (en) Rp215 chimeric antigen receptor construct and methods of making and using same
WO2024210072A1 (ja) キメラタンパク質、核酸、ベクター、ｔ細胞又はｎｋ細胞、医薬組成物、組み合わせ物、組み合わせ医薬、及び標的抗原結合タンパク質
HK40115184A (en) Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
HK40076158A (en) Novel chimeric antigen receptor and use thereof
HK40076158B (en) Novel chimeric antigen receptor and use thereof
HK40062446B (en) Engineered immune cell targeting bcma and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221025

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20221025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240116

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250603